PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, No.100 Western 4th Ring Road, Beijing 100039, China; Wuhan Huoshenshan Hospital, Wuhan, China.\', \'Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; National Industrial Base for Stem Cell Engineering Products, Tianjin, China.\', \'Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, No.100 Western 4th Ring Road, Beijing 100039, China.\', \'Department of Infectious Disease, General Hospital of Central Theater Command, Wuhan, China.\', \'Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, No.100 Western 4th Ring Road, Beijing 100039, China; The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.\', \'Department of Radiology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.\', \'Wuhan Kingmed Center for Clinical Laboratory Co., Ltd., Wuhan, China.\', \'National Industrial Base for Stem Cell Engineering Products, Tianjin, China; VCANBIO Cell&Gene Engineering Corp., Ltd., Tianjin, China.\', \'Department of Gastroenterology, Changzheng Hospital, Naval Medical University, 415 Fengyang Road, Shanghai, 200003, China; Optical Valley Branch of Maternal and Child Hospital of Hubei Province, Wuhan, China. Electronic address: weifenxie@medmail.com.cn.\', \'Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, No.100 Western 4th Ring Road, Beijing 100039, China; Wuhan Huoshenshan Hospital, Wuhan, China. Electronic address: fswang302@163.com.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S2352-3964(21)00583-110.1016/j.ebiom.2021.103789
?:hasPublicationType
?:journal
  • EBioMedicine
is ?:pmid of
?:pmid
?:pmid
  • 34963099
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.895
?:rankingScore_hIndex
  • 26
?:title
  • Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34963099>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34963099>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all